Comments
Loading...

Neurocrine Biosciences Analyst Ratings

NBIXNASDAQ
Logo brought to you by Benzinga Data
$101.38
1.281.28%
At close: -
$101.38
0.000.00%
After Hours: 4:16 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$219.00
Lowest Price Target1
$114.00
Consensus Price Target1
$159.84

Neurocrine Biosciences Analyst Ratings and Price Targets | NASDAQ:NBIX | Benzinga

Neurocrine Biosciences Inc has a consensus price target of $159.84 based on the ratings of 25 analysts. The high is $219 issued by Oppenheimer on August 2, 2024. The low is $114 issued by BMO Capital on October 17, 2024. The 3 most-recent analyst ratings were released by Needham, RBC Capital, and UBS on April 15, 2025, April 14, 2025, and April 4, 2025, respectively. With an average price target of $137.33 between Needham, RBC Capital, and UBS, there's an implied 35.46% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Dec 24
2
Jan
9
Feb
2
Mar
3
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
RBC Capital
UBS
JP Morgan
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for Neurocrine Biosciences

Buy NowGet Alert
04/15/2025Buy Now36.12%Needham
Ami Fadia51%
→ $138UpgradeHold → BuyGet Alert
04/14/2025Buy Now35.14%RBC Capital
Brian Abrahams47%
$138 → $137UpgradeSector Perform → OutperformGet Alert
04/04/2025Buy Now35.14%UBS
Ashwani Verma40%
$154 → $137MaintainsBuyGet Alert
03/26/2025Buy Now81.5%JP Morgan
Anupam Rama56%
$183 → $184MaintainsOverweightGet Alert
03/07/2025Buy Now47.96%Morgan Stanley
Jeffrey Hung50%
$185 → $150Assumes → OverweightGet Alert
02/24/2025Buy Now82.48%HC Wainwright & Co.
Andrew Fein54%
$185 → $185ReiteratesBuy → BuyGet Alert
02/21/2025Buy Now82.48%HC Wainwright & Co.
Andrew Fein54%
$185 → $185ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now60.78%Guggenheim
Yatin Suneja47%
$165 → $163MaintainsBuyGet Alert
02/10/2025Buy Now82.48%HC Wainwright & Co.
Andrew Fein54%
$190 → $185MaintainsBuyGet Alert
02/07/2025Buy Now45.99%RBC Capital
Brian Abrahams47%
$154 → $148MaintainsSector PerformGet Alert
02/07/2025Buy Now45%Wedbush
Laura Chico44%
$157 → $147MaintainsOutperformGet Alert
02/07/2025Buy Now60.78%Canaccord Genuity
Sumant Kulkarni41%
$172 → $163MaintainsBuyGet Alert
02/07/2025Buy Now82.48%HC Wainwright & Co.
Andrew Fein54%
$190 → $185MaintainsBuyGet Alert
02/07/2025Buy NowNeedham
Ami Fadia51%
ReiteratesHold → HoldGet Alert
02/07/2025Buy Now76.56%B of A Securities
Tazeen Ahmad55%
$184 → $179MaintainsBuyGet Alert
02/04/2025Buy Now82.48%Morgan Stanley
Jeffrey Hung50%
$170 → $185MaintainsOverweightGet Alert
01/30/2025Buy Now73.6%UBS
Ashwani Verma40%
$162 → $176MaintainsBuyGet Alert
01/08/2025Buy Now59.79%UBS
Ashwani Verma40%
$142 → $162MaintainsBuyGet Alert
12/23/2024Buy Now57.82%Piper Sandler
David Amsellem69%
$160 → $160ReiteratesOverweight → OverweightGet Alert
12/23/2024Buy Now62.75%Barclays
Carter Gould56%
$160 → $165MaintainsOverweightGet Alert
12/20/2024Buy NowNeedham
Ami Fadia51%
ReiteratesHold → HoldGet Alert
12/16/2024Buy Now45.99%Wedbush
Laura Chico44%
$148 → $148ReiteratesOutperform → OutperformGet Alert
12/16/2024Buy Now87.41%HC Wainwright & Co.
Andrew Fein54%
$190 → $190ReiteratesBuy → BuyGet Alert
11/11/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
11/01/2024Buy Now87.41%HC Wainwright & Co.
Andrew Fein54%
$190 → $190ReiteratesBuy → BuyGet Alert
10/31/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
10/30/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
10/29/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
10/17/2024Buy Now12.45%BMO Capital
Evan Seigerman64%
$128 → $114MaintainsMarket PerformGet Alert
10/10/2024Buy Now52.89%Raymond James
Danielle Brill41%
→ $155Reinstates → OutperformGet Alert
10/08/2024Buy Now31.19%RBC Capital
Brian Abrahams47%
$133 → $133ReiteratesSector Perform → Sector PerformGet Alert
10/04/2024Buy Now31.19%RBC Capital
Brian Abrahams47%
$136 → $133MaintainsSector PerformGet Alert
09/16/2024Buy Now52.89%Cantor Fitzgerald
Charles Duncan68%
$155 → $155ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now57.82%Barclays
Carter Gould56%
$180 → $160MaintainsOverweightGet Alert
08/29/2024Buy Now52.89%Cantor Fitzgerald
Charles Duncan68%
$170 → $155MaintainsOverweightGet Alert
08/29/2024Buy Now26.26%BMO Capital
Evan Seigerman64%
$142 → $128MaintainsMarket PerformGet Alert
08/29/2024Buy Now56.84%Piper Sandler
David Amsellem69%
$131 → $159UpgradeNeutral → OverweightGet Alert
08/29/2024Buy Now34.15%RBC Capital
Brian Abrahams47%
$143 → $136MaintainsSector PerformGet Alert
08/29/2024Buy Now87.41%HC Wainwright & Co.
Andrew Fein54%
$190 → $190ReiteratesBuy → BuyGet Alert
08/29/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
08/19/2024Buy Now86.43%Jefferies
Akash Tewari43%
$177 → $189MaintainsBuyGet Alert
08/07/2024Buy Now78.54%JP Morgan
Anupam Rama56%
$173 → $181MaintainsOverweightGet Alert
08/05/2024Buy Now87.41%HC Wainwright & Co.
Andrew Fein54%
$160 → $190MaintainsBuyGet Alert
08/02/2024Buy Now41.05%RBC Capital
Brian Abrahams47%
$136 → $143MaintainsSector PerformGet Alert
08/02/2024Buy Now77.55%Guggenheim
Yatin Suneja47%
$170 → $180MaintainsBuyGet Alert
08/02/2024Buy Now55.85%Citigroup
David Hoang35%
$150 → $158MaintainsNeutralGet Alert
08/02/2024Buy Now116.02%Oppenheimer
Jay Olson61%
$216 → $219MaintainsOutperformGet Alert
08/02/2024Buy Now77.55%Barclays
Carter Gould56%
$169 → $180MaintainsOverweightGet Alert
08/02/2024Buy Now77.55%Baird
Brian Skorney57%
$157 → $180MaintainsOutperformGet Alert
08/01/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
07/25/2024Buy Now52.89%Cantor Fitzgerald
Charles Duncan68%
$155 → $155ReiteratesOverweight → OverweightGet Alert
07/25/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
07/12/2024Buy Now67.69%Morgan Stanley
Jeffrey Hung50%
$160 → $170MaintainsOverweightGet Alert
07/10/2024Buy Now70.65%JP Morgan
Anupam Rama56%
$169 → $173MaintainsOverweightGet Alert
06/12/2024Buy Now57.82%Morgan Stanley
Jeffrey Hung50%
$160 → $160MaintainsOverweightGet Alert
05/29/2024Buy Now49.93%Wedbush
Laura Chico44%
$152 → $152ReiteratesOutperform → OutperformGet Alert
05/28/2024Buy Now90.37%UBS
Ashwani Verma40%
$174 → $193MaintainsBuyGet Alert
05/14/2024Buy Now72.62%Evercore ISI Group
Cory Kasimov68%
→ $175Initiates → OutperformGet Alert
05/03/2024Buy Now47.96%Citigroup
David Hoang35%
$140 → $150MaintainsNeutralGet Alert
05/02/2024Buy Now61.77%Canaccord Genuity
Sumant Kulkarni41%
$154 → $164MaintainsBuyGet Alert
05/02/2024Buy Now67.69%Guggenheim
Yatin Suneja47%
$164 → $170MaintainsBuyGet Alert
05/02/2024Buy Now66.7%Barclays
Carter Gould56%
$150 → $169MaintainsOverweightGet Alert
05/02/2024Buy Now36.12%BMO Capital
Evan Seigerman64%
$129 → $138MaintainsMarket PerformGet Alert
05/02/2024Buy Now113.06%Oppenheimer
Jay Olson61%
$200 → $216MaintainsOutperformGet Alert
05/02/2024Buy Now57.82%HC Wainwright & Co.
Andrew Fein54%
$150 → $160MaintainsBuyGet Alert
05/02/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
05/01/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
04/24/2024Buy Now47.96%HC Wainwright & Co.
Andrew Fein54%
$150 → $150ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now67.69%Wells Fargo
Mohit Bansal69%
$140 → $170UpgradeEqual-Weight → OverweightGet Alert
04/24/2024Buy Now97.28%Oppenheimer
Jay Olson61%
$200 → $200MaintainsOutperformGet Alert
04/23/2024Buy NowNeedham
Ami Fadia51%
Reiterates → HoldGet Alert
04/17/2024Buy Now45%Wedbush
Laura Chico44%
$147 → $147ReiteratesOutperform → OutperformGet Alert
04/10/2024Buy Now52.89%Cantor Fitzgerald
Charles Duncan68%
→ $155ReiteratesOverweight → OverweightGet Alert
03/20/2024Buy Now55.85%JP Morgan
Anupam Rama56%
$148 → $158MaintainsOverweightGet Alert
03/13/2024Buy Now97.28%Oppenheimer
Jay Olson61%
$170 → $200MaintainsOutperformGet Alert
02/23/2024Buy Now45.99%JP Morgan
Anupam Rama56%
$154 → $148MaintainsOverweightGet Alert
02/08/2024Buy Now38.09%Citigroup
David Hoang35%
$141 → $140MaintainsNeutralGet Alert
02/08/2024Buy Now38.09%Mizuho
Uy Ear60%
$116 → $140MaintainsNeutralGet Alert
02/08/2024Buy Now38.09%Wells Fargo
Mohit Bansal69%
$127 → $140MaintainsEqual-WeightGet Alert
01/25/2024Buy Now50.92%Goldman Sachs
Chris Shibutani55%
$134 → $153MaintainsBuyGet Alert
01/23/2024Buy Now47.96%Barclays
Carter Gould56%
$145 → $150MaintainsOverweightGet Alert
12/18/2023Buy Now42.04%Stifel
Paul Matteis41%
$141 → $144MaintainsBuyGet Alert
12/13/2023Buy Now25.27%Wells Fargo
Mohit Bansal69%
$110 → $127MaintainsEqual-WeightGet Alert
12/13/2023Buy Now25.27%Citigroup
David Hoang35%
→ $127Initiates → NeutralGet Alert
12/12/2023Buy Now34.15%Deutsche Bank
Neena Bitritto-Garg59%
→ $136Initiates → BuyGet Alert
12/07/2023Buy Now47.96%Canaccord Genuity
Sumant Kulkarni41%
→ $150ReiteratesBuy → BuyGet Alert
11/10/2023Buy Now-1.36%BMO Capital
Evan Seigerman64%
$111 → $100MaintainsMarket PerformGet Alert
11/10/2023Buy Now19.35%RBC Capital
Brian Abrahams47%
$128 → $121MaintainsSector PerformGet Alert
11/10/2023Buy Now12.45%Mizuho
Uy Ear60%
$116 → $114MaintainsNeutralGet Alert
11/03/2023Buy Now14.42%Mizuho
Uy Ear60%
$113 → $116MaintainsNeutralGet Alert
11/01/2023Buy Now26.26%RBC Capital
Brian Abrahams47%
$123 → $128MaintainsSector PerformGet Alert
11/01/2023Buy Now-1.36%Piper Sandler
David Amsellem69%
$95 → $100MaintainsNeutralGet Alert
11/01/2023Buy Now43.03%Raymond James
Danielle Brill41%
$135 → $145MaintainsOutperformGet Alert
10/24/2023Buy NowCantor Fitzgerald
Charles Duncan68%
Assumes → OverweightGet Alert
10/06/2023Buy Now62.75%Oppenheimer
Jay Olson61%
$160 → $165MaintainsOutperformGet Alert
10/06/2023Buy Now47.96%HC Wainwright & Co.
Andrew Fein54%
$146 → $150MaintainsBuyGet Alert
09/13/2023Buy Now42.04%Canaccord Genuity
Sumant Kulkarni41%
$132 → $144MaintainsBuyGet Alert
09/13/2023Buy Now11.46%Mizuho
Uy Ear60%
→ $113ReiteratesNeutral → NeutralGet Alert
09/13/2023Buy Now35.14%Wedbush
Laura Chico44%
$120 → $137MaintainsOutperformGet Alert
09/13/2023Buy Now32.18%JP Morgan
Anupam Rama56%
$133 → $134MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Neurocrine Biosciences (NBIX) stock?

A

The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Needham on April 15, 2025. The analyst firm set a price target for $138.00 expecting NBIX to rise to within 12 months (a possible 36.12% upside). 71 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?

A

The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Needham, and Neurocrine Biosciences upgraded their buy rating.

Q

When was the last upgrade for Neurocrine Biosciences (NBIX)?

A

The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.

Q

When was the last downgrade for Neurocrine Biosciences (NBIX)?

A

There is no last downgrade for Neurocrine Biosciences.

Q

When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.

Q

Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?

A

While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a upgraded with a price target of $0.00 to $138.00. The current price Neurocrine Biosciences (NBIX) is trading at is $101.38, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch